News Releases

May 05, 2022
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
Financial
May 04, 2022
Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
Corporate
May 03, 2022
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
Pipeline
Apr 28, 2022
Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022
Financial
Apr 26, 2022
2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment
Products
Mar 14, 2022
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Corporate
Mar 11, 2022
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
Products
Mar 08, 2022
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Corporate
Mar 02, 2022
Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
Corporate
Feb 24, 2022
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
Financial
Feb 23, 2022
New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test
Products
Feb 16, 2022
Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022
Corporate
Feb 14, 2022
Myriad Genetics to Present at Two Upcoming Healthcare Conferences
Corporate
Jan 05, 2022
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference
Corporate
Jan 04, 2022
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service
Corporate